Physician profile
Marisa J Roach
NPI 1275794083
$4,178.71
in general payments reported to CMS, 2019-2025
28 companies · $972 in 2025
The $972 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $350 · 2022: $499 · 2023: $1,115 · 2024: $1,243 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,152 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,151.84 |
| Education | $177.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $877.57 | 2023-2025 | Gemtesa, Orgovyx |
| Myriad Genetic Laboratories, INC. | $489.02 | 2023-2025 | Prolaris, Myrisk |
| Astellas Pharma US INC | $444.30 | 2021-2025 | Xtandi |
| Janssen Biotech, INC. | $416.94 | 2022-2025 | Erleada |
| Procept Biorobotics Corporation | $296.03 | 2024-2025 | Aquabeam System |
| Teleflex LLC | $278.81 | 2021-2024 | Urolift |
| Antares Pharma, INC. | $199.02 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Ferring Pharmaceuticals INC. | $193.54 | 2024-2025 | Adstiladrin |
| Merck Sharp & Dohme LLC | $177.93 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $152.61 | 2022-2025 | |
| Urovant Sciences INC | $92.46 | 2021-2022 | |
| Accord Healthcare, INC. | $70.01 | 2024-2025 | |
| Coloplast Corp | $68.75 | 2023-2024 | Speedicath |
| Medtronic, INC. | $60.62 | 2023-2024 | Interstim |
| Tolmar Pharmaceuticals, INC. | $49.10 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $48.11 | 2024 | |
| Dentsply Ih Ab | $36.18 | 2025 | Lofric |
| Axonics, INC. | $31.24 | 2023 | Bulkamid |
| Ethicon US, LLC | $28.54 | 2025 | Vistaseal |
| Blue Earth Diagnostics | $28.08 | 2025 | Posluma |
| Dendreon Pharmaceuticals LLC | $21.35 | 2023 | Provenge |
| Immunitybio, INC. | $19.38 | 2024 | |
| Olympus America INC. | $17.72 | 2023 | Itind System |
| Janssen Pharmaceuticals, INC | $17.68 | 2021 | |
| Progenics Pharmaceuticals, INC. | $17.54 | 2023 | Pylarify |
| Agiliti Surgical, INC. | $16.86 | 2023 | Soltive, Sonablate |
| Telix Pharmaceuticals | $15.47 | 2023 | Illuccix |
| Optinose US, INC. | $13.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marisa Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.